



## D2PCR™ Buffer

The D2PCR™ Buffer for direct-to-PCR applications combined with ultrafast thermocyclers allows genotyping in < 1 hour

### Ready-to-use PCR templates



The D2PCR™ Buffer is designed to offer a rapid and simple protocol for generating ready-to-use PCR templates. These templates can directly be used for the subsequent PCR without any further processing of the DNA.

The D2PCR™ Buffer is compatible with ViennaLab singleplex and multiplex RealFast™ Assays.

When used with RealFast™ Assays and combined with ultrafast cycling on the MIC\*) qPCR Cycler, complete genotyping from drawing blood to final result can be accomplished in less than 1 hour. Moreover, RealFast™ Assays can be run on D2PCR™ Buffer templates also on various common real-time PCR instruments.

### ViennaLab D2PCR™ Buffer

- Rapid and simple protocol
- Less than 1 hour from sample to result
- Ready-to-use buffer
- Compatible with ViennaLab singleplex and multiplex RealFast™ Assays
- Compatible with various real-time PCR instruments

\*) Magnetic Induction Cycler ([www.biomolecularsystems.com](http://www.biomolecularsystems.com))

#### REF:

D2PCR™ Buffer: 2-030 (100 extractions)

For more details please visit: [www.viennalab.com](http://www.viennalab.com)

**ViennaLab RealFast™ Assays for single marker detection**

Area	Product	REF 100 / 32 Rxn	Label	Application
<b>Carbohydrate Intolerance</b>	<b>LCT -13910C&gt;T</b> RealFast™ Assay	7-150 / 7-153	CE/IVD	Detects the most common polymorphism in the <i>lactase (LCT)</i> gene causing lactase non-persistence
<b>Cardiovascular Diseases (CVD)</b>	<b>FGB -455G&gt;A</b> RealFast™ Assay	7-230 / 7-233	CE/IVD	Identifies homozygosity for the -455G>A <i>fibrinogen beta-chain (FGB)</i> allele which may increase susceptibility to atherothrombosis in at-risk patients
	<b>FV Leiden</b> RealFast™ Assay	7-110 / 7-113	CE/IVD	Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the <i>Factor V (FV)</i> gene
	<b>FXII 46C&gt;T</b> RealFast™ Assay	7-240 / 7-243	CE/IVD	Identifies patients with the unfavorable TT genotype for <i>Factor XII (FXII)</i> , who may have an increased susceptibility to thrombotic disorders
	<b>FXIII V34L</b> RealFast™ Assay	7-250 / 7-253	CE/IVD	Identifies carriers of the protective 34L variant of Factor XIII (FXIII) among at-risk patients of hereditary thrombophilia
	<b>MTHFR 677C&gt;T</b> RealFast™ Assay	7-160 / 7-163	CE/IVD	Detect common mutations in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease
	<b>MTHFR 1298A&gt;C</b> RealFast™ Assay	7-170 / 7-173	CE/IVD	
	<b>PAI-1 4G/5G</b> RealFast™ Assay	7-180 / 7-183	CE/IVD	Detects the 4G risk allele in the <i>plasminogen activator inhibitor-1 (PAI-1)</i> gene, associated with cardiovascular disease and pregnancy complications
	<b>PTH 20210G&gt;A</b> RealFast™ Assay	7-120 / 7-123	CE/IVD	Detects the second most important genetic risk factor for venous thromboembolism in the <i>prothrombin (PTH)</i> gene
<b>Genetic Predisposition</b>	<b>HLA-B27</b> RealFast™ Assay	7-620 / 7-623	CE/IVD	Detects the human leukocyte antigen-B (HLA-B) 27 allele, which is associated with ankylosing spondylitis
<b>Haemochromatosis</b>	<b>HFE C282Y</b> RealFast™ Assay	7-130 / 7-133	CE/IVD	Detect common mutations in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1
	<b>HFE H63D</b> RealFast™ Assay	7-140 / 7-143	CE/IVD	
<b>Pharmacogenetics</b>	<b>HLA-B5701</b> RealFast™ Assay	7-610 / 7-613	CE/IVD	Detects human leukocyte antigen-B (HLA-B) 5701 allele, which is associated with hypersensitivity to the anti-HIV drug abacavir
	<b>IL28B</b> RealFast™ Assay	7-200 / 7-203	CE/IVD	Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients
	<b>SLC01B1c.521T&gt;C</b> RealFast™ Assay	7-210 / 7-213	CE/IVD	Detects a variant in human <i>solute carrier organic anion transporter family member 1B1 (SLC01B1)</i> gene in patients who are at higher risk for developing statin-induced myopathy
	<b>VKORC1 -1639G&gt;A</b> RealFast™ Assay	7-190 / 7-193	CE/IVD	Detects the most important polymorphism in the <i>Vitamin K Epoxide Reductase Complex 1 (VKORC1)</i> gene associated with interindividual dose requirements for oral anticoagulants

**ViennaLab RealFast™ Assays for multiplex testing - save costs and sample material**

<b>Cardiovascular Diseases (CVD)</b>	<b>FV-PTH mp<sup>x</sup> <sup>NEW!</sup></b> RealFast™ Assay	7-115 / 7-118	CE/IVD	Simultaneous detection of the most important thrombophilic mutations 1691G>A in the <i>Factor V</i> gene and 20210G>A in the <i>prothrombin</i> gene
	<b>MTHFR mp<sup>x</sup> <sup>NEW!</sup></b> RealFast™ Assay	7-165 / 7-168	CE/IVD	Simultaneous detection of the most common two mutations in the <i>MTHFR</i> gene: 677C>T and 1298A>C
<b>COPD/ AAT deficiency</b>	<b>AAT mp<sup>x</sup> <sup>NEW! *</sup></b> RealFast™ Assay	7-265 / 7-268	CE/IVD	Detects *S and *Z variants of the <i>SERPINA1</i> gene predisposing individuals to chronic obstructive pulmonary disease (COPD) and liver disease due to deficiency of alpha-1 antitrypsin (AAT)
<b>Haemochromatosis</b>	<b>HFE mp<sup>x</sup> <sup>NEW!</sup></b> RealFast™ Assay	7-135 / 7-138	CE/IVD	Simultaneous detection of the two most common mutations in the <i>HFE</i> gene: H63D and C282Y
<b>Pharmacogenetics</b>	<b>CYP2C9 mp<sup>x</sup> <sup>NEW! *</sup></b> RealFast™ Assay	7-225 / 7-228	CE/IVD	Simultaneous detection of <i>CYP2C9</i> *2 (c.430C>T) and <i>CYP2C9</i> *3 (c.1075A>C) polymorphisms to determine the drug response of coumarin-based anticoagulation therapy

\*) not suitable for ultrafast cycling on the MIC qPCR Cycler



Manufacturer:

**ViennaLab Diagnostics GmbH**

Gaudenzdorfer Guertel 43-45

A-1120 Vienna, Austria

www.viennalab.com

t: (+43-1) 8120156-0

f: (+43-1) 8120156-19

e: info@viennalab.com

Distributor:



More details available at [www.viennalab.com](http://www.viennalab.com)